-
Prof. Michael Sela
Importance of negligible amounts of a partner in antibody combinationsAn aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.Collaboration with: G. Mahlknecht , Y. Yarden G. MahlknechtSynergy of antibodies towards decreasing pancreatic cancer.Collaboration with: R. Maron, B. Schechter, Y. YardenTowards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Collaboration with: E. Witsch, Y. YardenMechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.Collaboration with: R. ArnonEffective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.Collaboration with: Y. YardenMonoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.Collaboration with: B. Schechter, Y. YardenSynergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.Collaboration with: B. Schechter, Y. Yarden
-
Prof. Michael Sela
Importance of negligible amounts of a partner in antibody combinationsAn aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.Collaboration with: G. Mahlknecht , Y. Yarden G. MahlknechtSynergy of antibodies towards decreasing pancreatic cancer.Collaboration with: R. Maron, B. Schechter, Y. YardenTowards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Collaboration with: E. Witsch, Y. YardenMechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.Collaboration with: R. ArnonEffective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.Collaboration with: Y. YardenMonoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.Collaboration with: B. Schechter, Y. YardenSynergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.Collaboration with: B. Schechter, Y. Yarden
-
Prof. Michael Sela
An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.Collaboration with: G. Mahlknecht , Y. Yarden G. MahlknechtSynergy of antibodies towards decreasing pancreatic cancer.Collaboration with: R. Maron, B. Schechter, Y. YardenTowards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Collaboration with: E. Witsch, Y. YardenMechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.Collaboration with: R. ArnonEffective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.Collaboration with: Y. YardenMonoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.Collaboration with: B. Schechter, Y. YardenSynergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.Collaboration with: B. Schechter, Y. Yarden
-
Prof. Michael Sela
An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.Collaboration with: G. Mahlknecht , Y. Yarden G. MahlknechtSynergy of antibodies towards decreasing pancreatic cancer.Collaboration with: R. Maron, B. Schechter, Y. YardenTowards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Collaboration with: E. Witsch, Y. YardenMechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.Collaboration with: R. ArnonEffective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.Collaboration with: Y. YardenMonoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.Collaboration with: B. Schechter, Y. YardenSynergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.Collaboration with: B. Schechter, Y. Yarden
-
Prof. Michael Sela
An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.Collaboration with: G. Mahlknecht , Y. Yarden G. MahlknechtSynergy of antibodies towards decreasing pancreatic cancer.Collaboration with: R. Maron, B. Schechter, Y. YardenTowards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Collaboration with: E. Witsch, Y. YardenMechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.Collaboration with: R. ArnonEffective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.Collaboration with: Y. YardenMonoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.Collaboration with: B. Schechter, Y. YardenSynergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.Collaboration with: B. Schechter, Y. Yarden
-
Prof. Michael Sela
An aptamer strategy to target oncogenic signaling in ErbB2 carrying human tumors.Collaboration with: G. Mahlknecht , Y. Yarden G. MahlknechtSynergy of antibodies towards decreasing pancreatic cancer.Collaboration with: R. Maron, B. Schechter, Y. YardenTowards vaccination: Generation of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.Collaboration with: E. Witsch, Y. YardenMechanism of action of Copolymer 1 (Copaxone), a therapeutic vaccine against multiple sclerosis.Collaboration with: R. ArnonEffective synergism by anti ErbB-2 mAb combinations comprising one mAb against the dimerization site of ErbB-2.Collaboration with: Y. YardenMonoclonal antibodies (mAbs) to ErbB-1 and ErbB-2 receptors and their role in potential anti-tumor strategy.Collaboration with: B. Schechter, Y. YardenSynergistic effects of combinations of mAb against distinct epitopes on EGFR/ErbB-1 and ErbB-2 receptors: accelerated receptor aggregation, down regulation and inhibition of tumor growth.Collaboration with: B. Schechter, Y. Yarden